Literature DB >> 19655026

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.

Christopher J Hoimes1, Wm Kevin Kelly.   

Abstract

Entities:  

Year:  2009        PMID： 19655026      PMCID： PMC2719855          DOI： 10.1016/j.uct.2009.03.001

Source DB:  PubMed          Journal:  Update Cancer Ther        ISSN： 1872-115X


× No keyword cloud information.
  12 in total

1.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

2.  Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.

Authors:  James W Denham; Allison Steigler; Chantelle Wilcox; David S Lamb; David Joseph; Chris Atkinson; John Matthews; Keen-Hun Tai; Nigel A Spry; David Christie; Paul S Gleeson; Peter B Greer; Catherine D'Este
Journal:  Lancet Oncol       Date:  2008-10-15       Impact factor: 41.316

3.  Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database.

Authors:  G D Grossfeld; D M Stier; S C Flanders; J M Henning; W Schonfeld; K Warolin; P R Carroll
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

Review 4.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

Review 5.  Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.

Authors:  Laurence Collette; Tomasz Burzykowski; Fritz H Schröder
Journal:  Eur J Cancer       Date:  2006-05-30       Impact factor: 9.162

6.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

7.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Hedy Mameghan; Sandra Turner; John Matthews; Ian Franklin; Chris Atkinson; John North; Michael Poulsen; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Gillian Duchesne; Olga Kovacev; Catherine D'Este
Journal:  Lancet Oncol       Date:  2005-11       Impact factor: 41.316

8.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

9.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 10.  Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.

Authors:  Eric J Small; Mack Roach
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.